Xuyong Wei
Overview
Explore the profile of Xuyong Wei including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
109
Citations
1021
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
61.
Wei X, Su R, Yang M, Pan B, Lu J, Lin H, et al.
Transl Oncol
. 2022 Apr;
20:101422.
PMID: 35430532
Purpose: Hepatocellular carcinoma (HCC) is characterized by a poor long-term prognosis and high mortality rate. Serum alpha-fetoprotein (AFP) levels show great prognostic value in patients undergoing hepatectomy. This study aims...
62.
Wei X, Yang M, Pan B, Zhang X, Lin H, Li W, et al.
Hepatol Commun
. 2022 Apr;
6(8):2182-2197.
PMID: 35429130
Hepatocellular carcinoma (HCC) is one of the most prevalent malignancies; its recurrence is associated with high mortality and poor recurrence-free survival and is affected by multisystem and multilevel pathological changes....
63.
Lu J, Zhou W, Wei X, Wang K, Zhou L, Xu X
Diagnostics (Basel)
. 2022 Mar;
12(3).
PMID: 35328124
Although clear cell renal cell carcinoma (ccRCC) is easy to diagnose early and most can be radically resected, nearly one-third of patients still experience metastases after radical nephrectomy. The most...
64.
Yang M, Khan A, Lu D, Wei X, Shu W, Xu C, et al.
Front Med (Lausanne)
. 2022 Mar;
9:772048.
PMID: 35308496
Background: A high model of end-stage liver disease (MELD) score (>30) adversely affects outcomes even if patients receive prompt liver transplantation (LT). Therefore, balanced allocation of donor grafts is indispensable...
65.
Pan B, Wei X, Xu X
Cancer Cell Int
. 2022 Jan;
22(1):41.
PMID: 35090441
Animal models are crucial tools for evaluating the biological progress of human cancers and for the preclinical investigation of anticancer drugs and cancer prevention. Various animals are widely used in...
66.
Wei Q, Zhou J, Wang K, Zhang X, Chen J, Lu D, et al.
Front Med (Lausanne)
. 2021 Dec;
8:775212.
PMID: 34957150
Early allograft dysfunction (EAD) after liver transplantation (LT) accompanies poor prognosis. This study aims to explore the relationship between pretransplant intrahepatic proteins and the incidence of EAD, and the value...
67.
Zhuo J, Lu D, Lin Z, Yang X, Yang M, Wang J, et al.
Cell Death Dis
. 2021 Nov;
12(12):1084.
PMID: 34785656
Cytokeratin 19-positive (CK19+) hepatocellular carcinoma (HCC) is an aggressive subtype characterized by early recurrence and chemotherapy tolerance. However, there is no specific therapeutic option for CK19+ HCC. The correlation between...
68.
Zhuo J, Lu D, Wang J, Lian Z, Zhang J, Li H, et al.
Chin J Cancer Res
. 2021 Sep;
33(4):470-479.
PMID: 34584372
Objective: Patient-derived xenograft (PDX) models provide a promising preclinical platform for hepatocellular carcinoma (HCC). However, the molecular features associated with successful engraftment of PDX models have not been revealed. Methods:...
69.
Khan A, Wei X, Xu X
J Hepatocell Carcinoma
. 2021 Sep;
8:1089-1115.
PMID: 34522691
Portal vein involvement is considered one of the most fearful complications of hepatocellular carcinoma (HCC). Portal vein tumor thrombosis (PVTT) is associated with aggressive tumor biology (high grade), high tumor...
70.
Yang X, Lu D, Wang R, Lian Z, Lin Z, Zhuo J, et al.
Cell Prolif
. 2021 Sep;
54(10):e13116.
PMID: 34469018
Objectives: The discrepancy between supply and demand of organ has led to an increased utilization of steatotic liver for liver transplantation (LT). Hepatic steatosis, however, is a major risk factor...